Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Morning Research: Celgene, Edwards Lifesciences, Forest Laboratories, and Peregrine Pharma



  Morning Research: Celgene, Edwards Lifesciences, Forest Laboratories, and
                               Peregrine Pharma

PR Newswire

LONDON, July 31, 2013

LONDON, July 31, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

On Tuesday, July 30, 2013, shares in healthcare companies ended on a mixed
note, tracking the broader market. The major movers in the sector included
Celgene Corporation (NASDAQ: CELG), Edwards Lifesciences Corp. (NYSE: EW),
Forest Laboratories Inc. (NYSE: FRX), and Peregrine Pharmaceuticals (NASDAQ:
PPHM). AAAResearchReports.com has released full comprehensive research on
CELG, EW, FRX, and PPHM. These free technical analyses can be downloaded by
signing up at:

http://www.aaaresearchreports.com/register/  

Shares in Celgene Corporation moved higher on Tuesday, extending their gains
from previous trading sessions. The company's shares hit a 52-week high of
$146.22 before finishing the day 1.90% higher at $145.37. A total of 2.87
million shares were traded which is above the daily average volume of 2.72
million. The stock has gained 3.36% in the last three trading sessions as
compared to a loss of 0.25% in the S&P 500. Moreover, the stock is currently
trading above its 50-day and 200-day moving averages. Download free report on
CELG upon registration at:

http://www.AAAResearchReports.com/CELG073113.pdf

Edwards Lifesciences Corp.'s stock edged lower on Tuesday, ending the session
at $70.51, down 0.70% from its previous closing price. The company's shares
fluctuated between $70.33 and $71.44. A total of 0.81 million shares were
traded which is below the daily average volume of 1.12 million. The company's
shares have gained 4.93% in the last one month and 10.53% in the last three
months as compared to a gain of 4.96% and 5.53% in the S&P 500 during the
respective periods. EW technical report can be accessed for free by signing up
at:

http://www.AAAResearchReports.com/EW073113.pdf

Shares in Forest Laboratories Inc. edged higher on Tuesday, reversing some of
their recent losses. The company's shares oscillated between $43.58 and $44.20
before finishing the day 0.44% higher at $43.77. A total of 0.84 million
shares were traded which is below the daily average volume of 1.84 million.
Forest Laboratories' shares have fallen by 0.50% in the last three trading
sessions, thus underperforming the S&P 500. Despite Tuesday's pullback, the
stock is still trading around its 52-week high of $44.87. The free report on
FRX can be downloaded by signing up now at:

http://www.AAAResearchReports.com/FRX073113.pdf

Peregrine Pharmaceuticals struggled for direction on Tuesday before finishing
the day flat. The company's shares ended the day at $1.43 after oscillating
between $1.43 and $1.47. A total of 1.34 million shares were traded which is
below the daily average volume of 2.40 million. Peregrine Pharmaceuticals'
shares have gained 10.85% in the last one month, hence outperforming the S&P
500. A free report on PPHM can be accessed by registering at:

http://www.AAAResearchReports.com/PPHM073113.pdf

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE AAA Research Reports

Contact: AAAresearchreports.com Phone #: + 1 (646) 396-9126
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement